Hence, a combination therapy targeting the anti-inflammatory (such as IL-6 blockades) (13) and anti-fibrotic pathways (such as Pirfenidone) (36) may be a potential therapeutical strategy for long COVID with pulmonary fibrosis. The gene discussed is IL6; the disease is pulmonary fibrosis.